Daily Endocrinology Research Analysis
Three impactful endocrinology studies stand out today: a Nature Metabolism paper introduces fluorescent dual GLP1R/GIPR agonist probes that map cellular targets in pancreas and brain, advancing incretin biology. A Hypertension study delineates a mechanistic pathway whereby dihydrotestosterone elevates blood pressure via gut microbiota–derived TMAO and hypothalamic inflammation. A prospective JAMA Surgery cohort supports the long-term durability of active surveillance for small, low-risk papillar
Summary
Three impactful endocrinology studies stand out today: a Nature Metabolism paper introduces fluorescent dual GLP1R/GIPR agonist probes that map cellular targets in pancreas and brain, advancing incretin biology. A Hypertension study delineates a mechanistic pathway whereby dihydrotestosterone elevates blood pressure via gut microbiota–derived TMAO and hypothalamic inflammation. A prospective JAMA Surgery cohort supports the long-term durability of active surveillance for small, low-risk papillary thyroid cancer, especially in older adults.
Research Themes
- Incretin biology and dual GLP1R/GIPR targeting
- Sex hormones–gut microbiota–cardiovascular axis
- Active surveillance strategies in low-risk thyroid cancer
Selected Articles
1. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain.
The authors engineered lipidated and non-lipidated fluorescent dual GLP1R/GIPR agonist probes (daLUXendins) and demonstrated potent dual-receptor agonism with robust labeling of rodent and human islet cells (β>α=δ) and GLP1R-rich brain regions in vivo. These tools reduce receptor selectivity bias and enable direct visualization of dual-agonist cellular targets across tissues.
Impact: This work delivers first-in-class fluorescent dual-agonist probes that map incretin-receptor targets in human and rodent tissues, addressing a key knowledge gap limiting optimization of GLP1R/GIPR therapeutics.
Clinical Implications: By enabling precise tissue and cell-level target mapping for dual incretin agonists, these probes can guide dosing, safety assessment (off-target profiling), and rational design of next-generation GLP1R/GIPR agents with improved efficacy and tolerability.
Key Findings
- Developed lipidated and non-lipidated fluorescent GLP1R/GIPR dual agonist probes (daLUXendin/daLUXendin+).
- Probes showed potent dual agonism with reduced functional selectivity bias for mouse GLP1R over GIPR.
- Robust labeling of rodent and human islet cells with β cells > α cells = δ cells signal intensity.
- Systemic administration strongly labeled GLP1R-enriched brain regions, enabling in vivo target visualization.
Methodological Strengths
- Tool development with functional pharmacology validation across GLP1R and GIPR.
- Cross-species demonstration including rodent in vivo imaging and human islet labeling.
Limitations
- Preclinical study; therapeutic impact inferred rather than demonstrated in humans.
- Quantitative receptor occupancy and long-term biodistribution/safety not fully characterized.
Future Directions: Apply probes to patient-derived tissues and in vivo models to quantify receptor engagement, map off-targets, and correlate regional targeting with metabolic and appetite outcomes under different dual-agonist regimens.
Dual agonists targeting glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are breakthrough treatments for patients with type 2 diabetes and obesity. Compared to GLP1R agonists, dual agonists show superior efficacy for glucose lowering and weight reduction. However, delineation of dual agonist cell targets remains challenging. Here, we develop and test daLUXendin and daLUXendin+, non-lipidated and lipidated fluorescent GLP1R/GIPR dual agonist probes, and use them to visualize cellular targets. daLUXendins are potent GLP1R/GIPR dual agonists that advantageously show less functional selectivity for mouse GLP1R over mouse GIPR. daLUXendins label rodent and human pancreatic islet cells, with a signal intensity of β cells > α cells = δ cells. Systemic administration of daLUXendin strongly labels GLP1R
2. Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer.
In a prospective single-center cohort (n=200; median 71 months), active surveillance for small, low-risk papillary thyroid cancer had no disease-specific mortality and a 23.9% crossover to surgery, mainly due to progression or patient preference. Age strongly influenced durability: 5-year crossover rates were highest in <45 years (41.5%) and lowest in ≥65 years (5.1%).
Impact: Provides age-stratified, long-term prospective data supporting the safety and durability of active surveillance in low-risk PTC, informing shared decision-making and guideline implementation.
Clinical Implications: Active surveillance is a robust option for older patients with small, low-risk PTC, with low crossover rates; counseling should emphasize higher crossover likelihood in patients <45 years and clarify triggers for intervention.
Key Findings
- No thyroid cancer–related deaths or distant metastases over median 71 months of follow-up.
- Overall 23.9% crossover from active surveillance to surgery; 56.8% due to progression and 40.5% due to patient preference.
- Five-year cumulative crossover: 41.5% (<45 years), 20.9% (45–64 years), and 5.1% (≥65 years).
Methodological Strengths
- Prospective design with long-term follow-up and explicit competing risk analysis.
- Clear, age-stratified reporting of crossover indications and rates.
Limitations
- Single-center study may limit generalizability.
- Selection bias possible in patient choice of surveillance versus immediate surgery.
Future Directions: Multi-center registries with standardized imaging criteria and patient-reported outcomes to refine risk stratification and thresholds for intervention during surveillance.
IMPORTANCE: In managing early-stage cancers, active surveillance (AS) may be preferentially favored by older individuals. In counseling patients, it is important to understand the durability of AS in the context of age. OBJECTIVE: To evaluate the durability of AS in patients with small, low-risk papillary thyroid cancer (PTC) according to age at the time of choosing AS. DESIGN, SETTING, AND PARTICIPANTS: This single-center, prospective, long-term follow-up cohort study was conducted at a tertiary care hospital in Toronto, Ontario, Canada. Adult patients with small, localized, low-risk PTC less than 2 cm in maximal diameter were enrolled between May 2016 and February 2021. The clinical outcome data were analyzed up to the time point of May 25, 2025, and final data analysis was performed in June 2025. EXPOSURE: All patients were offered the choice of AS or thyroid surgery. MAIN OUTCOMES AND MEASURES: The primary outcome was the overall rate of AS crossover to definitive treatment (treatment completed or recommended by an investigator) and the indications. Cumulative crossover incidence function curves were examined according to age, with death from other causes as the competing risk. RESULTS: A total of 200 patients (155 patients under AS and 45 who had immediate surgery) were followed up for a median (IQR) duration of 71 (59-84) months. Overall mean (SD) age was 52.0 (14.9) years, and 153 patients (76.5%) were female. There were no observed thyroid cancer-related deaths or any distant metastatic disease. The overall crossover rate from AS was 23.9% (37/155; 32 completed treatment, 3 declined surgery for disease progression, and 2 awaiting treatment). Crossover reasons included disease progression (56.8% [21/37]), patient preference (40.5% [15/37]), and ultrasound imaging limitations precluding accurate tumor measurement under active surveillance (tumor border not clearly distinguishable from heterogeneous echotexture of the thyroid parenchyma in a patient with Hashimoto thyroiditis; 2.6% [1/37]). The 5-year age-stratified cumulative overall crossover incidence rates were 41.5% (95% CI, 25.6%-56.8%) in patients younger than 45 years, 20.9% (95% CI, 12.3%-31.1%) in those aged 45 to 64 years, and 5.1% (95% CI, 0.9%-15.2%) in those aged 65 years and older (P < .001). CONCLUSION AND RELEVANCE: This single-center Canadian cohort study found that AS is a durable long-term management strategy for small, low -risk PTC, particularly in older individuals. Older individuals may be less likely to cross over to surgery after choosing AS.
3. Sex Hormone Androgen Elevates Blood Pressure Through Gut Microbiota-TMAO Pathway.
In spontaneously hypertensive rats, dihydrotestosterone (DHT) increased blood pressure by reshaping gut microbiota and elevating TMA/TMAO, with TMAO accumulating in plasma and the hypothalamic paraventricular nucleus where it associated with inflammation and sympathetic activation. Manipulations including antibiotics, gonadectomy, hormone replacement, and TMAO blockade support a causal gut microbiota–TMAO pathway mediating androgen-driven hypertension.
Impact: Defines a mechanistic endocrine–microbiome–neurocardiovascular axis linking androgens to hypertension via TMAO and hypothalamic sympathetic activation, highlighting actionable pathways for sex-specific therapy.
Clinical Implications: Suggests evaluating TMAO pathways and microbiota modulation as potential adjuncts in male-predominant or androgen-excess hypertension and informs consideration of sex hormones in BP pathophysiology.
Key Findings
- DHT elevated blood pressure in gonadectomized SHRs with hormone replacement and reshaped gut microbiota.
- DHT increased microbiota-derived TMA/TMAO; TMAO accumulated in plasma and hypothalamic PVN.
- TMAO accumulation correlated with inflammation and sympathetic activation; antibiotic/TMAO blockade modulated BP responses.
Methodological Strengths
- Multiple orthogonal interventions (antibiotics, gonadectomy, hormone replacement, TMAO modulation) establishing causality.
- Integration of metabolic (TMAO), microbiome, neuroinflammatory, and physiological BP readouts.
Limitations
- Findings derived from rat models; human translational relevance requires validation.
- Pubertal SHR context and specific dosing may limit generalizability across ages and etiologies.
Future Directions: Translational studies measuring TMAO, androgen status, and central sympathetic markers in men with hypertension; interventional microbiota or TMAO-targeted trials stratified by sex.
BACKGROUND: Hypertension is a leading risk factor for all-cause mortality worldwide, affecting ≈1.3 billion people. Imbalanced gut microbiota contributes to blood pressure elevation. We recently reported sex differences in the responses of gut microbiota to environmental stimuli, such as salt, with male gut microbiota being more vulnerable to induce high blood pressure than female microbiota. In this study, we investigated the mechanisms by which gut microbiota regulate blood pressure in a sex-dependent manner. METHODS: Antibiotic treatment, gonadectomy, sex hormone replenishment, and treatment with trimethylamine N-oxide or its blocker were performed in male and female spontaneously hypertensive rats. RESULTS: We observed sex differences in gut microbiota composition and sex-specific blood pressure responses to antibiotic treatment in pubertal spontaneously hypertensive rats. In gonadectomized rats treated with sex hormones, we found that the male sex hormone dihydrotestosterone elevated blood pressure, reshaped gut microbiota, and increased levels of microbiota-derived metabolites, trimethylamine and trimethylamine N-oxide. The accumulation of trimethylamine N-oxide in plasma and the paraventricular nucleus of the hypothalamus was associated with inflammation and sympathetic activation. CONCLUSIONS: These findings underscore the mechanistic role of dihydrotestosterone in gut microbiota-mediated sex-specific blood pressure regulation and suggest that targeting the gut microbiota-treatment with trimethylamine N-oxide pathway may provide new therapeutic strategies for male hypertension.